Clinical Trials Logo

Refractory Hypertension clinical trials

View clinical trials related to Refractory Hypertension.

Filter by:
  • None
  • Page 1

NCT ID: NCT04213963 Recruiting - Atrial Fibrillation Clinical Trials

Prospective Study on Primary Aldosteronism in Resistant Hypertension

PrePARe
Start date: September 1, 2011
Phase:
Study type: Observational

Prevalence of primary aldosteronism (PA) in resistant hypertension is not clear. In addition, emerging evidence supports the role of elevated serum aldosterone in promoting cardiovascular disease, independently from high blood pressure (BP) levels, but current data on this issue are heterogeneous.

NCT ID: NCT03223272 Completed - Clinical trials for Refractory Hypertension

Mechanisms of Refractory Hypertension (Reserpine)

Start date: July 23, 2015
Phase: Phase 2
Study type: Interventional

The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.

NCT ID: NCT01656096 Completed - Clinical trials for Refractory Hypertension

Renal Sympathetic Denervation in Mild Refractory Hypertension

Start date: July 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the benefit of renal sympathetic denervation in patients with mild refractory hypertension

NCT ID: NCT00899977 Terminated - Clinical trials for Refractory Hypertension

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

Start date: May 2009
Phase: Phase 1/Phase 2
Study type: Interventional

A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP > 140 mmHg and a DBP > 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.

NCT ID: NCT00812695 Completed - Clinical trials for Obstructive Sleep Apnea

Effects of Continuous Positive Airway Pressure (CPAP) in Patients With Resistant Hypertension and Obstructive Sleep Apnea (OSA)

Start date: October 2008
Phase: Phase 3
Study type: Interventional

Obstructive sleep apnea (OSA) is an important cause of refractory hypertension but the impact of treatment with continuous positive airway pressure (CPAP) is not completely understood. The aim of this project is to study the effects of CPAP on blood pressure control and its influences on cardiac remodeling and arterial stiffness in patients with refractory hypertension and moderate or severe OSA.

NCT ID: NCT00746902 Completed - Clinical trials for Refractory Hypertension

Study of the Relationships Between Refractory Hypertension, Overweight/Obesity and Sleep Apnea Syndrome

RHOOSAS
Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate the links between blood pressure (BP), overweight or obesity, and sleep apnea syndrome (SAS), by studying a large cohort of subjects suffering from refractory hypertension. Primary objective - To compare plasmatic leptin levels in patients suffering from refractory hypertension depending on whether or not they experience SAS. Secondary objectives - To ascertain what determines the difference in plasmatic leptin concentrations in patients suffering from refractory hypertension depending on whether or not they experience SAS. - To characterise BP readings (from clinical and ambulatory (ABPM) measurements) in patients suffering from refractory hypertension depending on whether or not they experience SAS. - To characterise metabolic parameters (lipids, glycaemia, adiponectin) and sympathetic nervous system effectors (adrenaline, noradrenaline and metanephrines) in patients suffering from refractory hypertension depending on whether or not they experience SAS. - To characterise BP readings, metabolic parameters and sympathetic nervous system effectors in patients suffering from refractory hypertension according to the severity of the SAS (in those who experience this problem). - To study, in patients with both SAS and refractory hypertension, the impact of nasal continuous positive airway pressure (CPAP) treatment on BP readings, metabolic parameters and sympathetic nervous system effectors, by comparing those who are compliant with the CPAP regimen with those who are non-compliant.